Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money

71% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

  • Updates
  • autonomous vehicles
  • biotechnology
  • digital transformation
  • electric vehicles
  • fintech
  • gaming
  • mobile payments

Top Stories

Tencent posts highest quarterly revenue growth in over a year

In today’s top stories, China’s video gaming giant Tencent posted its fastest growth in quarterly revenue for over a year. Elsewhere, automaker Stellantis has warned that electric vehicle manufacturing in the UK could become “uncompetitive and unsustainable”, while Elon Musk announced on Tuesday that Tesla is to launch its first advertisements. The US FTC is suing to block Amgen’s acquisition of Horizon Therapeutics on the grounds that it would stifle competition. Lastly, autonomous driving company Boldly is teaming up with Estonian start-up Auve Tech to bring self-driving buses to the streets of Japan. 

Stellantis threatens UK factory closure

Vauxhall maker Stellantis [STLA] has issued a warning to the UK government: renegotiate a Brexit rule on where parts are sourced from, or its UK factories could close. The current terms of the rule stipulate that, to avoid tariffs, from 2024, 45% of the value of an EV must come from parts sourced within the UK or EU. Stellantissays it cannot satisfy the requirements, and unless the rules change, electric vehicle manufacturing in the UK will become “uncompetitive and unsustainable”.

Amgen–Horizon deal in doubt

The US Federal Trade Commission (FTC) is suing to block Amgen’s [AMGN] $27.8bn acquisition of Horizon Therapeutics [HZNP] on the grounds that it would “stifle competition for thyroid eye disease and chronic refractory gout treatments”. While biotech M&A activity has been picking up, with several big pharma companies striking deals, the FTC argues that “rampant consolidation” has given the industry an excuse to “exorbitantly hike prescription drug prices”. Amgen’s share price fell 2.4% Tuesday. 

Softbank-backed self-driving buses 

Autonomous driving company Boldly, which is backed by investment powerhouse Softbank [9984.T], is teaming up with Estonian start-up Auve Tech in the hope of speeding up efforts to bring self-driving buses to at least 50 locations in Japan by 2025. In an interview with Bloomberg, Boldly CEO Yuki Saji said: “SoftBank’s biggest strengths are in mobile networks and, going forward, cars will be among the products most in need of both mobility and connectivity.

Tencent boosted by 11% revenue growth

China’s video gaming giant Tencent [0700.HK] posted its fastest growth in quarterly revenue for over a year. Sales in 2022 had been hampered by Beijing’s freezing of gaming licences, which had prevented new titles from being released. But the regulatory picture has improved since the start of 2023. Tencent also benefitted from “domestic consumption recovery” in the three months to the end of March, chairman and CEO Ma Huateng said in a statement alongside the results.

Tesla targets advertising

Elon Musk announced on Tuesday that Tesla [TSLA] will launch its first advertisements. Speaking at the company’s investor day on Tuesday, Musk said that “there are amazing features and functionality about Teslas that people just don’t know about”, but promoting these via traditional channels, like the company’s Twitter account, is “like preaching to the choir, and the choir is already convinced”.

Disclaimer Past performance is not a reliable indicator of future results.

CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.

The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.

CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.

*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.

Continue reading for FREE

Latest articles